A citation-based method for searching scientific literature

Tímea Varga, Anikó Somogyi, Gábor Barna, Barna Wichmann, Géza Nagy, Károly Rácz, László Selmeci, Gábor Firneisz. Pathol Oncol Res 2011
Times Cited: 39







List of co-cited articles
252 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.
Daniela Lamers, Susanne Famulla, Nina Wronkowitz, Sonja Hartwig, Stefan Lehr, D Margriet Ouwens, Kristin Eckardt, Jean M Kaufman, Mikael Ryden, Stefan Müller,[...]. Diabetes 2011
370
30

Serum dipeptidyl peptidase 4 activity in children with type 1 diabetes mellitus.
Atsushi Iwabuchi, Tomohiro Kamoda, Makoto Saito, Hiroki Nozue, Isho Izumi, Takeki Hirano, Ryo Sumazaki. J Pediatr Endocrinol Metab 2013
19
57

Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
Lei Tian, Jie Gao, Jianqiang Hao, Yu Zhang, Huimin Yi, Timothy D O'Brien, Robert Sorenson, Jian Luo, Zhiguang Guo. Endocrinology 2010
84
25

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet Med 2011
89
23

Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J Clin Endocrinol Metab 2014
72
23

Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker.
Gábor Firneisz, Tímea Varga, Gabriella Lengyel, János Fehér, Dóra Ghyczy, Barna Wichmann, László Selmeci, Zsolt Tulassay, Károly Rácz, Anikó Somogyi. PLoS One 2010
94
23

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
61
20

Significant elevation of serum dipeptidyl peptidase-4 activity in young-adult type 1 diabetes.
Saeko Osawa, Dan Kawamori, Naoto Katakami, Mitsuyoshi Takahara, Fumie Sakamoto, Takashi Katsura, Tetsuyuki Yasuda, Hideaki Kaneto, Munehide Matsuhisa, Taka-Aki Matsuoka,[...]. Diabetes Res Clin Pract 2016
17
47

Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro.
Henrike Sell, Matthias Blüher, Nora Klöting, Raphaela Schlich, Miriam Willems, Florian Ruppe, Wolfram Trudo Knoefel, Arne Dietrich, Barbara A Fielding, Peter Arner,[...]. Diabetes Care 2013
130
17

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
J Andrew Pospisilik, Jennifer Martin, Timothy Doty, Jan A Ehses, Nathalie Pamir, Francis C Lynn, Shalea Piteau, Hans-Ulrich Demuth, Christopher H S McIntosh, Raymond A Pederson. Diabetes 2003
270
15

CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes.
M D Gorrell, V Gysbers, G W McCaughan. Scand J Immunol 2001
275
15


Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Anne-Marie Lambeir, Christine Durinx, Simon Scharpé, Ingrid De Meester. Crit Rev Clin Lab Sci 2003
609
15


Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
Roger Yazbeck, Gordon S Howarth, Catherine A Abbott. Trends Pharmacol Sci 2009
178
15

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
Jacob Jelsing, Niels Vrang, Søren B van Witteloostuijn, Michael Mark, Thomas Klein. J Endocrinol 2012
35
17

The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes.
Yunjuan Zhao, Lin Yang, Xiangbing Wang, Zhiguang Zhou. Diabetes Metab Res Rev 2014
39
15

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus.
E Mannucci, L Pala, S Ciani, G Bardini, A Pezzatini, I Sposato, F Cremasco, A Ognibene, C M Rotella. Diabetologia 2005
158
12

Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.
Jakob Ryskjaer, Carolyn F Deacon, Richard D Carr, Thure Krarup, Sten Madsbad, Jens Holst, Tina Vilsbøll. Eur J Endocrinol 2006
143
12


Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26).
Bertram Bengsch, Bianca Seigel, Tobias Flecken, Julia Wolanski, Hubert E Blum, Robert Thimme. J Immunol 2012
100
12

A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
Noriko Satoh-Asahara, Yousuke Sasaki, Hiromichi Wada, Mayu Tochiya, Azusa Iguchi, Reiko Nakagawachi, Shinji Odori, Shigeo Kono, Koji Hasegawa, Akira Shimatsu. Metabolism 2013
124
12

[Elevated serum dipeptidyl peptidase-4 activity in type 1 diabetes mellitus: a direct comparison].
Tímea Varga, Gábor Firneisz, Géza Nagy, Anikó Somogyi. Orv Hetil 2010
11
45

One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin.
Marcos M Lima-Martínez, Ernesto Guerra-Alcalá, Miguel Contreras, José Nastasi, Janelle A Noble, Constantin Polychronakos. Endocrinol Diabetes Metab Case Rep 2014
12
41

C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study.
Odd Erik Johansen, Bernhard O Boehm, Valdemar Grill, Peter A Torjesen, Sudipta Bhattacharya, Sanjay Patel, Kristiane Wetzel, Hans-Juergen Woerle. Diabetes Care 2014
41
12

Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA).
Xia Li, Lan Liao, Xiang Yan, Gan Huang, Jian Lin, Minxiang Lei, Xiangbing Wang, Zhiguang Zhou. Diabetes Metab Res Rev 2009
70
10


The structure and function of CD26 in the T-cell immune response.
C Morimoto, S F Schlossman. Immunol Rev 1998
327
10


Circulating CD26 is negatively associated with inflammation in human and experimental arthritis.
Nathalie Busso, Nicolai Wagtmann, Christian Herling, Veronique Chobaz-Péclat, Angelika Bischof-Delaloye, Alexander So, Eric Grouzmann. Am J Pathol 2005
157
10


Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.
A D Dobrian, Q Ma, J W Lindsay, K A Leone, K Ma, J Coben, E V Galkina, J L Nadler. Am J Physiol Endocrinol Metab 2011
105
10

Sitagliptin exerts an antinflammatory action.
Antoine Makdissi, Husam Ghanim, Mehul Vora, Kelly Green, Sanaa Abuaysheh, Ajay Chaudhuri, Sandeep Dhindsa, Paresh Dandona. J Clin Endocrinol Metab 2012
170
10

CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production.
Ryo Hatano, Kei Ohnuma, Junpei Yamamoto, Nam H Dang, Chikao Morimoto. Immunology 2013
47
10

Can clinical factors estimate insulin resistance in type 1 diabetes?
K V Williams, J R Erbey, D Becker, S Arslanian, T J Orchard. Diabetes 2000
273
10

CD26: a negative selection marker for human Treg cells.
Francisco J Salgado, Amparo Pérez-Díaz, Nora M Villanueva, Olaya Lamas, Pilar Arias, Montserrat Nogueira. Cytometry A 2012
31
12

Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism.
Masayuki Miyazaki, Masaki Kato, Kosuke Tanaka, Masatake Tanaka, Motoyuki Kohjima, Kazuhiko Nakamura, Munechika Enjoji, Makoto Nakamuta, Kazuhiro Kotoh, Ryoichi Takayanagi. Mol Med Rep 2012
91
10



Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S).
Takuya Awata, Akira Shimada, Taro Maruyama, Yoichi Oikawa, Nobuyuki Yasukawa, Susumu Kurihara, Yumi Miyashita, Masako Hatano, Yuichi Ikegami, Masafumi Matsuda,[...]. Diabetes Ther 2017
24
16

No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes.
Markus Walter, Thomas Kaupper, Kerstin Adler, Johannes Foersch, Ezio Bonifacio, Anette-G Ziegler. Diabetes Care 2010
79
7

Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.
S Alice Long, Karen Cerosaletti, Paul L Bollyky, Megan Tatum, Heather Shilling, Sheng Zhang, Zhong-Yin Zhang, Catherine Pihoker, Srinath Sanda, Carla Greenbaum,[...]. Diabetes 2010
194
7




Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes.
Shelley Lindley, Colin M Dayan, Amanda Bishop, Bart O Roep, Mark Peakman, Timothy I M Tree. Diabetes 2005
587
7

Beneficial autoimmunity in Type 1 diabetes mellitus.
Ehud Hauben, Maria Grazia Roncarolo, Uri Nevo, Michal Schwartz. Trends Immunol 2005
25
12

Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study.
E Hyppönen, E Läärä, A Reunanen, M R Järvelin, S M Virtanen. Lancet 2001
7


Autoreactive T cells in healthy individuals.
Nancy A Danke, David M Koelle, Cassian Yee, Sucheta Beheray, William W Kwok. J Immunol 2004
235
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.